ggpp

HGGPPS-IN-1 is an analogue of C-2-substituted thienopyrimidine-based bisphosphonates (C2-ThP-BPs). HGGPPS-IN-1 has an effective inhibitory effect on human geranyl geranyl pyrophosphate synthase (hGGPPS). HGGPPS-IN-1 can selectively induce apoptosis of multiple myeloma (MM) cells. HGGPPS-IN-1 showed anti-myeloma activity in vivo.

hGGPPS-IN-2 is an analogue of C-2 substituted thienopyrimidinyl bisphosphonates (C2-ThP-BPs) and is a potent inhibitor of human geranylgeranyl pyrophosphate synthase (hGGPPS). hGGPPS-IN-2 targets multiple myeloma (MM) cells, induces selective apoptosis, and shows anti-myeloma effects in vivo. It has shown anti-myeloma effects in vivo.

Compound 13h (hGGPPS-IN-3) is a potent inhibitor of human geranylgeranyl pyrophosphate synthase (hGGPPS), characterized as a C-2-substituted thienopyrimidine-based bisphosphonate analogue (C2-ThP-BPs). It selectively induces apoptosis in multiple myeloma (MM) cells and demonstrates antimyeloma activity in vivo [1].

Digeranyl bisphosphonate (DGBP) is a potent geranylgeranyl pyrophosphate (GGPP) synthase inhibitor that impedes the geranyl pyrophosphorylation of Rac1 and induces autophagy without causing apoptosis.

Geranylgeranyl Pyrophosphate triammonium (GGPP triammonium) is a metabolite involved in protein geranylgeranylation, modulating endothelial cell proliferation and apoptosis during mouse embryonic angiogenesis. GGPP triammonium amplifies T(reg) differentiation by increasing IL-2 expression, improving DSS-induced colitis, useful in cancer research.

Farnesyl pyrophosphate (Farnesyl diphosphate), a 15-carbon isoprenoid from the mevalonate (MVA) pathway, functions as a metabolic intermediary and TRPM2 (TRP Channel) agonist, facilitating TRPM2 channel opening and ion influx. It is crucial in synthesizing cholesterol, ubiquinones, and geranyl-geranyl pyrophosphate (GGPP), and in protein farnesylation decoration [1].